Market Overview

UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on HCP on Model Update

Share:
Related HCP
Oppenheimer Offers Deep Technical Dive Into Financials, Says Goldman, JP Morgan, Morgan Stanley 'Top Buy Ideas'
Top Performing Industries For May 15, 2015
Omega Healthcare Investors, Inc. (OHI) Dividend Stock Analysis (GuruFocus)

In a report published Friday, J.P. Morgan reiterated its Neutral rating on HCP (NYSE: HCP), and raised its price target from $48.00 to $50.00.

J.P. Morgan noted, “We retain our Neutral rating on HCP due to a number of factors. On the valuation front, the stock trades at slight premiums to the health care REIT averages (particularly on an AFFO basis), which we do believe is justified considering its improved growth profile following recent investment activity and lease restructuring. However, we continue to maintain our bias toward more economically leveraged property types at this point in the cycle.”

HCP closed on Thursday at $48.88.

Latest Ratings for HCP

DateFirmActionFromTo
May 2015RBC CapitalMaintainsUnderperform
May 2015BMO CapitalMaintainsUnderperform
Apr 2015BMO CapitalInitiates Coverage onUnderperform

View More Analyst Ratings for HCP
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (HCP)

Around the Web, We're Loving...